Unibest

Pharmaceutical intermediates

Lapatinib Intermediates

2 pharmaceutical intermediates for Lapatinib. Indication: Breast Neoplasms.

提交项目All intermediates

About Lapatinib

Originator
Novartis Pharmaceuticals Corp
Indication
Breast Neoplasms
Approved Date
03/13/2007

Available intermediates

2 intermediates currently listed for Lapatinib. Request specifications, documentation or a quotation for any item below.

Lapatinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3-Chloro-4-(3-fluorobenzyloxy)aniline202197-26-0//
5-[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]quinazolin -6- yl]furan-2-carboxaldehyde231278-84-5//

Other programs under L

(LCZ696)LanifibranorLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodiumLenalidomide

Building toward Lapatinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →